{"organizations": [], "uuid": "a88c0109da0a770b1b183f0415eabee6ce03fc31", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180327.html", "section_title": "Archive News &amp; Video for Tuesday, 27 Mar 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-shield-therapeutics-says-receives/brief-shield-therapeutics-says-receives-eu-commission-approval-for-broadening-of-indication-for-feraccru-to-treatment-of-iron-deficiency-in-adults-idUSFWN1R9014", "country": "US", "domain_rank": 408, "title": "BRIEF-Shield Therapeutics Says ‍Receives EU Commission Approval For Broadening Of Indication For Feraccru To Treatment Of Iron Deficiency In Adults​", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.467, "site_type": "news", "published": "2018-03-27T15:18:00.000+03:00", "replies_count": 0, "uuid": "a88c0109da0a770b1b183f0415eabee6ce03fc31"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-shield-therapeutics-says-receives/brief-shield-therapeutics-says-receives-eu-commission-approval-for-broadening-of-indication-for-feraccru-to-treatment-of-iron-deficiency-in-adults-idUSFWN1R9014", "ord_in_thread": 0, "title": "BRIEF-Shield Therapeutics Says ‍Receives EU Commission Approval For Broadening Of Indication For Feraccru To Treatment Of Iron Deficiency In Adults​", "locations": [], "entities": {"persons": [], "locations": [{"name": "liechtenstein", "sentiment": "none"}, {"name": "norway", "sentiment": "none"}, {"name": "iceland", "sentiment": "none"}], "organizations": [{"name": "eu", "sentiment": "neutral"}, {"name": "reuters", "sentiment": "neutral"}, {"name": "eu commission approval for broadening of indication", "sentiment": "neutral"}, {"name": "eikon", "sentiment": "none"}, {"name": "ec", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "March 27 (Reuters) - Shield Therapeutics Plc:\n* SHIELD THERAPEUTICS - ‍RECEIVES EU COMMISSION APPROVAL FOR BROADENING OF INDICATION FOR FERACCRU TO TREATMENT OF IRON DEFICIENCY IN ADULTS​\n* SHIELD THERAPEUTICS - ‍EC ADOPTED DECISION TO EXTEND APPROVED INDICATION FOR FERACCRU TO INCLUDE TREATMENT OF ALL ADULTS WITH IRON DEFICIENCY OR WITHOUT ANAEMIA​\n* SHIELD THERAPEUTICS- ‍EUROPEAN COMMISSION APPROVAL GOVERNS MARKETING OF FERACCRU IN ALL 28 EU MEMBER COUNTRIES, AS WELL AS ICELAND, NORWAY AND LIECHTENSTEIN​ Source text for Eikon: Further company coverage:\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-03-27T15:18:00.000+03:00", "crawled": "2018-03-28T18:44:53.008+03:00", "highlightTitle": ""}